AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38377526 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment without pharmacogenetic testing)
Number of subjects: 0
Study 38377570 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention 1
Number of subjects: 0
Study 38377570 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention 2
Number of subjects: 0
Study 38377570 — intervention group
Group type: COMPARATOR
Intervention: Control Group (standard care)
Number of subjects: 0
Study 38377775 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched targeted therapy
Number of subjects: 93
Study 38377775 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-matched treatment
Number of subjects: 93
Study 38377775 — intervention group
Group type: EXPERIMENTAL
Intervention: AcSé ESMART trial
Number of subjects: 93
Study 38377775 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched targeted therapy outside a clinical trial
Number of subjects: 93
Study 38377775 — intervention group
Group type: COMPARATOR
Intervention: Successful sequencing analysis
Number of subjects: 93
Study 38377773 — intervention group
Group type: EXPERIMENTAL
Intervention: TLD-1 administered intravenously every 3 weeks up to a maximum of 9 cycles (6 for patients with prior anthracyclines) starting dose of 10 mg/m², maximum administered dose of 45 mg/m², RP2D defined at 40 mg/m².
Number of subjects: 30
Study 38377869 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin add-on treatment
Number of subjects: 0
Study 38378313 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography-derived fractional flow reserve (FFR)
Number of subjects: 102
Study 38378482 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk of hospital admission (percentiles 95-100)
Number of subjects: 40618
Study 38378482 — intervention group
Group type: COMPARATOR
Intervention: Low risk of hospital admission (percentiles <60)
Number of subjects: 40618
Study 38378482 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk of hospital admission (percentiles 85-100)
Number of subjects: 40618
Study 38378503 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-oriented mental health practice as measured by the Family-Focused Mental Health Practice Questionnaire (FFMHPQ)
Number of subjects: 475
Study 38378503 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace support for family-oriented practice
Number of subjects: 475
Study 38378503 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills and knowledge about the impact of mental illness and parenting
Number of subjects: 475
Study 38378503 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional support for family-oriented work
Number of subjects: 475
Study 38378522 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen patch cover (CPC)
Number of subjects: 241
Study 38378522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPC)
Number of subjects: 241
Study 38378532 — intervention group
Group type: EXPERIMENTAL
Intervention: EM Talk training (4-hour session with role-plays and active learning)
Number of subjects: 879
Study 38378532 — intervention group
Group type: EXPERIMENTAL
Intervention: EM Talk training
Number of subjects: 879
Study 38378568 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir administration (60 mL, followed by 120 mL after 12 h, then 240 mL daily)
Number of subjects: 54
Study 38378568 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir administration
Number of subjects: 54
Study 38378671 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic neurostimulation
Number of subjects: 0
Study 38378671 — intervention group
Group type: COMPARATOR
Intervention: Traditional approaches
Number of subjects: 0
Study 38378678 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (RANKL inhibitor)
Number of subjects: 0
Study 38378685 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet (FMD) - 3 cycles
Number of subjects: 0
Study 38378735 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based therapies (EBTs) including antithrombotic drugs
Number of subjects: 2003
Study 38378735 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction of all domains of secondary prevention
Number of subjects: 2003
Study 38378735 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall practice of secondary prevention
Number of subjects: 2003
Study 38378868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus durvalumab
Number of subjects: 29
Study 38378868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus durvalumab (in RAS wild type tumors)
Number of subjects: 29
Study 38378875 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 15
Study 38378875 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no specific intervention mentioned)
Number of subjects: 15
Study 38378937 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate loading dose
Number of subjects: 50
Study 38379100 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic gastrectomy (3D-LG)
Number of subjects: 438
Study 38379100 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic gastrectomy (2D-LG)
Number of subjects: 438
Study 38379394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 35
Study 38379394 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 35
Study 38379539 — intervention group
Group type: EXPERIMENTAL
Intervention: AlmegaPL (Omega-3 eicosapentaenoic polar-lipid rich extract from microalgae)
Number of subjects: 0
Study 38379539 — intervention group
Group type: EXPERIMENTAL
Intervention: AlmegaPL
Number of subjects: 0
Study 38379580 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive draping with adhesive incise drape
Number of subjects: 50
Study 38379580 — intervention group
Group type: COMPARATOR
Intervention: Standard shoulder arthroscopy drape
Number of subjects: 50
Study 38379859 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative levels of IGFBP2
Number of subjects: 192
Study 38379859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hit-proteins LDHB, VCAM1
Number of subjects: 192
Study 38379859 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause one-year mortality
Number of subjects: 192
Study 38379859 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 192
Study 38379859 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative myocardial infarction
Number of subjects: 192
Study 38379859 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke until hospital discharge
Number of subjects: 192
Study 38379866 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized resistance exercise program (at least 3 times per week over a 24-week period)
Number of subjects: 52
Study 38379866 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized resistance exercise program
Number of subjects: 52
Study 38380071 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTANE (multi-gene panel testing)
Number of subjects: 782
Study 38380342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer symptom management intervention
Number of subjects: 187
Study 38380342 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 187
Study 38380342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation tracking
Number of subjects: 187
Study 38380420 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg/Amlodipine 5 mg/Rosuvastatin 10 mg (TEL/ALD/RSV)
Number of subjects: 252
Study 38380420 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg/Atorvastatin 10 mg (ALD/ATV)
Number of subjects: 252
Study 38380438 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative iv morphine consumption with no versus only mild nausea, vomiting, sedation, and dizziness
Number of subjects: 0
Study 38380438 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative iv morphine consumption with mild versus moderate nausea, vomiting, sedation, and dizziness
Number of subjects: 0
Study 38380438 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative iv morphine consumption with moderate versus severe nausea, vomiting, sedation, and dizziness
Number of subjects: 0
Study 38380649 — intervention group
Group type: EXPERIMENTAL
Intervention: Interesterified palmitic acid-rich spread
Number of subjects: 0
Study 38380649 — intervention group
Group type: COMPARATOR
Intervention: Non-interesterified spread
Number of subjects: 0
Study 38380649 — intervention group
Group type: COMPARATOR
Intervention: Spreadable butter
Number of subjects: 0
Study 38380699 — intervention group
Group type: EXPERIMENTAL
Intervention: L-serine treatment for 52 weeks
Number of subjects: 24
Study 38380779 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin buccal bone group
Number of subjects: 26
Study 38380779 — intervention group
Group type: COMPARATOR
Intervention: Thick buccal bone group
Number of subjects: 26
Study 38380779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 38380807 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclic retinoid (ACR) treatment for 4 weeks
Number of subjects: 116
Study 38380807 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 116
Study 38380807 — intervention group
Group type: COMPARATOR
Intervention: Pre- and post-surgical patients with HCC
Number of subjects: 116
Study 38380807 — intervention group
Group type: COMPARATOR
Intervention: Patients with HCC
Number of subjects: 116
Study 38380940 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard initiation of Renal Replacement Therapy (RRT)
Number of subjects: 2693
Study 38380940 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated initiation of Renal Replacement Therapy (RRT)
Number of subjects: 2693
Study 38380940 — intervention group
Group type: COMPARATOR
Intervention: Control group (ANZ)
Number of subjects: 2693
Study 38380940 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional practice variation
Number of subjects: 2693
Study 38380992 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time machine learning alerts sent to primary team or rapid response team (RRT)
Number of subjects: 2740
Study 38380992 — intervention group
Group type: COMPARATOR
Intervention: Standard RRT activation criteria (control group)
Number of subjects: 2740
Study 38381061 — intervention group
Group type: EXPERIMENTAL
Intervention: KeraKlear (KK) foldable intrastromal keratoprosthesis
Number of subjects: 38
Study 38381068 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational drug users (41 patients, 12.6% positive multidrug test)
Number of subjects: 325
Study 38381068 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational drug users
Number of subjects: 325
Study 38381068 — intervention group
Group type: COMPARATOR
Intervention: Non-recreational drug users (control group)
Number of subjects: 325
Study 38381283 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA)
Number of subjects: 212
Study 38381283 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension (PH)-targeted therapy
Number of subjects: 212
Study 38381283 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 212
Study 38381283 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking distance (6MWD)
Number of subjects: 212
Study 38381283 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 212
Study 38381407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg per day)
Number of subjects: 611
Study 38381407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study 38381417 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (1-hour sessions, twice weekly for 15 weeks, up to 24 sessions)
Number of subjects: 93
Study 38381417 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (minimal needling, 1-hour sessions, twice weekly for 15 weeks, up to 24 sessions)
Number of subjects: 93
Study 38381417 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 93
Study 38381417 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 93
Study 38381476 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-Based Cognitive Behavioral Therapy (ICBT)
Number of subjects: 33
Study 38381476 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 33
Study 38381493 — intervention group
Group type: EXPERIMENTAL
Intervention: Group, blended eMBCT
Number of subjects: 24
Study 38381493 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual, unguided eMBCT
Number of subjects: 24
Study 38381495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 4
Study 38381495 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician feedback
Number of subjects: 4
Study 38381495 — intervention group
Group type: COMPARATOR
Intervention: Patient education and physician feedback
Number of subjects: 4
Study 38381664 — intervention group
Group type: EXPERIMENTAL
Intervention: Seladelpar (10 mg daily)
Number of subjects: 193
Study 38381664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 38381674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease group
Number of subjects: 1296
Study 38381674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessments in Alzheimer's disease group
Number of subjects: 1296
Study 38381674 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain imaging in Alzheimer's disease group
Number of subjects: 1296
Study 38381674 — intervention group
Group type: COMPARATOR
Intervention: Matched cognitively normal group
Number of subjects: 1296
Study 38381675 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusfertide
Number of subjects: 70
Study 38381675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 38381675 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusfertide and Placebo
Number of subjects: 70
Study 38381752 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-friendly community-based package of HIV services integrated with sexual and reproductive health services
Number of subjects: 1539
Study 38381752 — intervention group
Group type: EXPERIMENTAL
Intervention: Community delivery of antiretroviral therapy (ART)
Number of subjects: 1539
Study 38381905 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized/ultramicronized palmitoylethanolamide (m/umPEA) 600 mg twice daily for 3 months
Number of subjects: 98
Study 38381905 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not accept m/umPEA therapy)
Number of subjects: 98
Study 38381930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug in combination with paracetamol for 3 weeks
Number of subjects: 101
Study 38381948 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer acting injectable PrEP (LA PrEP)
Number of subjects: 0
Study 38381948 — intervention group
Group type: COMPARATOR
Intervention: Daily oral pre-exposure prophylaxis (PrEP)
Number of subjects: 0
Study 38381994 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant
Number of subjects: 478
Study 38381994 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 478
Study 38382001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 0
Study 38382001 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 0
Study 38382095 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning classifier models using LAS-breathprints
Number of subjects: 135
Study 38382095 — intervention group
Group type: COMPARATOR
Intervention: VOC-trained classifier model
Number of subjects: 135
Study 38382153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 720
Study 38382311 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 372
Study 38382311 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 372
Study 38382419 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet intervention
Number of subjects: 509
Study 38382698 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS) profiles for copy number variations (CNVs)
Number of subjects: 120
Study 38382698 — intervention group
Group type: EXPERIMENTAL
Intervention: Other CNVs (not whole chromosome)
Number of subjects: 120
Study 38382700 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 545
Study 38382823 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 risk communication intervention
Number of subjects: 900
Study 38382823 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 900
Study 38382875 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE
Number of subjects: 1171
Study 38382875 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab
Number of subjects: 1171
Study 38382875 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 1171
Study 38382912 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure-specific simulation skills training
Number of subjects: 83
Study 38382912 — intervention group
Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 83
Study 38382951 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding postoperative chest drains
Number of subjects: 2
Study 38382951 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative chest drains
Number of subjects: 2
Study 38382960 — intervention group
Group type: COMPARATOR
Intervention: 18F-FDG PET imaging
Number of subjects: 18
Study 38382960 — intervention group
Group type: COMPARATOR
Intervention: 68Ga-DOTANOC PET imaging
Number of subjects: 18
Study 38382960 — intervention group
Group type: COMPARATOR
Intervention: Correlation of uptake of 18F-FDG or 68Ga-DOTANOC
Number of subjects: 18
Study 38382960 — intervention group
Group type: COMPARATOR
Intervention: Secondary outcomes
Number of subjects: 18
Study 38383005 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive IV acetaminophen 15 mg/kg after anesthetic induction/before surgical incision
Number of subjects: 99
Study 38383005 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive IV acetaminophen 15 mg/kg at the end of surgery/before skin closure
Number of subjects: 99
Study 38383005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 38383268 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure hyperbaric oxygen therapy (HBOT), 8-week intervention (5 sessions per week)
Number of subjects: 33
Study 38383268 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 33
Study 38383268 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure hyperbaric oxygen therapy (HBOT)
Number of subjects: 33
Study 38383304 — intervention group
Group type: EXPERIMENTAL
Intervention: Female operators
Number of subjects: 8586
Study 38383304 — intervention group
Group type: COMPARATOR
Intervention: Male operators
Number of subjects: 8586
Study 38383304 — intervention group
Group type: EXPERIMENTAL
Intervention: Male operator gender
Number of subjects: 8586
Study 38383310 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool-based qPCR for TB diagnosis
Number of subjects: 1945
Study 38383323 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory strategies
Number of subjects: 0
Study 38383345 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid maintenance treatment (OMT)
Number of subjects: 176
Study 38383367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) - 3 months of treatment
Number of subjects: 0
Study 38383367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP) - 3 months of treatment
Number of subjects: 0
Study 38383367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Number of subjects: 0
Study 38383367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 0
Study 38383418 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging-guided personalized rTMS (fMRI-rTMS), high-frequency rTMS (10 Hz, 120% MT), 15 consecutive days, 30 minutes per session
Number of subjects: 80
Study 38383418 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group), coil flipped to 90 degrees, 15 consecutive days, 30 minutes per session
Number of subjects: 80
Study 38383418 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging-guided personalized rTMS (fMRI-rTMS)
Number of subjects: 80
Study 38383418 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 80
Study 38383426 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital psychological self-care (DPSC) with mid-treatment interview guidance
Number of subjects: 0
Study 38383426 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital psychological self-care (DPSC) with weekly written messages guidance
Number of subjects: 0
Study 38383426 — intervention group
Group type: COMPARATOR
Intervention: Digital psychological self-care (DPSC) without guidance
Number of subjects: 0
Study 38383458 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 417
Study 38383458 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-performing predictive models
Number of subjects: 417
Study 38383458 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control arm)
Number of subjects: 417
Study 38383461 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic left-sided hepatectomy (LLH)
Number of subjects: 172
Study 38383461 — intervention group
Group type: COMPARATOR
Intervention: Open left-sided hepatectomy (OLH)
Number of subjects: 172
Study 38383462 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (daily injections for at least 13 weeks before and 52 weeks after AF ablation)
Number of subjects: 0
Study 38383462 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 38383459 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder exercise with pain allowed
Number of subjects: 84
Study 38383459 — intervention group
Group type: COMPARATOR
Intervention: Shoulder exercise with pain avoided
Number of subjects: 84